Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients
Résumé
Conclusion: The combination of TTV load and QF-Ag or TTV load and QF-Mg could be useful in stratifying the risk of CMV reactivation in R+ KTR during the first post-transplant year and thereby have an impact on the duration of prophylaxis in these patients.
Mots clés
- Clinical trial registration: ClinicalTrials.gov registry
- identifier NCT02064699 Torquetenovirus
- cytomegalovirus
- QuantiFERON ® CMV
- kidney transplantation
- CMV-seropositive recipients
- Clinical trial registration: ClinicalTrials.gov registry identifier NCT02064699 Torquetenovirus cytomegalovirus QuantiFERON ® CMV kidney transplantation CMV-seropositive recipients
| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|---|
| Licence |